Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding

Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has launched today with £2.5m of seed funding from leading UK start-up investors UKI2S, LifeArc and Parkwalk. Primary use of funds is to take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies. Ikarovec was founded in 2019 by Chief Scientific Officer Dr Peter Widdowson, around intellectual property spun out of Quethera, which he founded and was bought by Astellas in 2018.

For further information, see Cambridge Network (https://www.cambridgenetwork.co.uk/news/ophthalmic-gene-therapy-company-ikarovec-launches-£25m-seed-funding)

Leave a Reply

Your email address will not be published. Required fields are marked *